Unknown

Dataset Information

0

Targeted apoptosis of myofibroblasts by elesclomol inhibits hypertrophic scar formation.


ABSTRACT: BACKGROUND:Hypertrophic scar (HS) is characterized by the increased proliferation and decreased apoptosis of myofibroblasts. Myofibroblasts, the main effector cells for dermal fibrosis, develop from normal fibroblasts. Thus, the stimulation of myofibroblast apoptosis is a possible treatment for HS. We aimed to explore that whether over-activated myofibroblasts can be targeted for apoptosis by anticancer drug elesclomol. METHODS:4',6-diamidino-2-phenylindole staining, flow cytometry, western blotting, collagen gel contraction and immunofluorescence assays were applied to demonstrate the proapoptotic effect of elesclomol in scar derived myofibroblasts and TGF-?1 induced myofibroblasts. The therapeutic potential of elesclomol was investigated by establishing rabbit ear hypertrophic scar models. FINDINGS:Both 4',6-diamidino-2-phenylindole staining and flow cytometry indicated that elesclomol targets myofibroblasts in vitro. Collagen gel contraction assay showed that elesclomol inhibited myofibroblast contractility. Flow cytometry and western blot analysis revealed that elesclomol resulted in excessive intracellular levels of reactive oxygen species(ROS), and caspase-3 and cytochrome c proteins. Moreover, compared with the control group, the elesclomol group had a significantly lower scar elevation index in vivo. Immunofluorescence assays for TUNEL and ?-smooth muscle actin indicated that elesclomol treatment increased the number of apoptotic myofibroblasts. INTERPRETATION:The above results indicate that elesclomol exerted a significant inhibitory effect on HS formation via targeted myofibroblast apoptosis associated with increased oxidative stress. Thus, elesclomol is a promising candidate drug for the treatment of myofibroblast-related diseases such as HS.

SUBMITTER: Feng Y 

PROVIDER: S-EPMC7132150 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeted apoptosis of myofibroblasts by elesclomol inhibits hypertrophic scar formation.

Feng Yi Y   Wu Jun-Jie JJ   Sun Zi-Li ZL   Liu Si-Yu SY   Zou Ming-Li ML   Yuan Zheng-Dong ZD   Yu Shun S   Lv Guo-Zhong GZ   Yuan Feng-Lai FL  

EBioMedicine 20200403


<h4>Background</h4>Hypertrophic scar (HS) is characterized by the increased proliferation and decreased apoptosis of myofibroblasts. Myofibroblasts, the main effector cells for dermal fibrosis, develop from normal fibroblasts. Thus, the stimulation of myofibroblast apoptosis is a possible treatment for HS. We aimed to explore that whether over-activated myofibroblasts can be targeted for apoptosis by anticancer drug elesclomol.<h4>Methods</h4>4',6-diamidino-2-phenylindole staining, flow cytometr  ...[more]

Similar Datasets

| S-EPMC5128858 | biostudies-literature
| S-EPMC9776926 | biostudies-literature
| S-EPMC8184471 | biostudies-literature
| S-EPMC7774882 | biostudies-literature
| S-EPMC7921104 | biostudies-literature
| S-EPMC9227726 | biostudies-literature
| S-EPMC7818462 | biostudies-literature
| S-EPMC5477152 | biostudies-literature
| S-EPMC7241611 | biostudies-literature
2022-06-03 | GSE190135 | GEO